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Abstract
Background: The current article is a systematic review concerning the efficacy and safety of
aripiprazole in the treatment of bipolar disorder.
Methods: A systematic Medline and repositories search concerning the usefulness of aripiprazole
in bipolar disorder was performed, with the combination of the words 'aripiprazole' and 'bipolar'.
Results: The search returned 184 articles and was last updated on 15 April 2009. An additional
search included repositories of clinical trials and previous systematic reviews specifically in order
to trace unpublished trials. There were seven placebo-controlled randomised controlled trials
(RCTs), six with comparator studies and one with add-on studies. They assessed the usefulness of
aripiprazole in acute mania, acute bipolar depression and during the maintenance phase in
comparison to placebo, lithium or haloperidol.
Conclusion: Aripiprazole appears effective for the treatment and prophylaxis against mania. The
data on bipolar depression are so far negative, however there is a need for further study at lower
dosages. The most frequent adverse effects are extrapyramidal signs and symptoms, especially
akathisia, without any significant weight gain, hyperprolactinaemia or laboratory test changes.
Background
The treatment of bipolar illness started with lithium and
Frederik Lange in the late 19th century [1]; later John Cade
in 1949 [2-4] and Mogens Schou with Poul Christian
Baastrup in the 1970s established its effectiveness [5-10].
Its long-term effects are still a matter of debate [11]. Anti-
convulsants are also considered to be useful in the treat-
ment of bipolar illness. In spite of what many clinicians
believe, there is no class effect for this group in bipolar dis-
order, since only valproate carbamazepine and lamotrig-
ine have strong data support. The use and usefulness of
antidepressant agents in bipolar disorder (BD) is contro-
versial. Guidelines suggest their cautious use and always
in combination with an antimanic agent [12]. This is
because antidepressants are believed to induce switching
to mania or hypomania [13-16], mixed episodes [17] and
rapid cycling, while research suggests that the use of anti-
manic agents might protect from such an effect at least
partially [18].
The most recent advances in bipolar treatment concern
the European Medicines Agency (EMEA) and the US Food
and Drug Administration (FDA) approval of olanzapine,
risperidone, quetiapine, ziprasidone and aripiprazole for
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the treatment of acute mania, the approval of quetiapine
and the olanzapine-fluoxetine combination against acute
bipolar depression and the approval of olanzapine,
quetiapine and aripiprazole for the maintenance phase.
This is an important development, because the treatment
of BD is as difficult and complex as the illness itself
[12,19-23]. The low reliability and validity of psychiatric
diagnosis perplexes the problem and makes the gathering
of scientific data difficult, because the diagnosis of BD in
particular is often made retrospectively and carries the risk
of memory distortions and biases. It is also well estab-
lished that an additional problem is that a specific and dif-
ferent treatment needs to be considered separately for
manic, hypomanic, mixed and bipolar depression epi-
sodes, as well as for unipolar depression [19,21,24]. The
complexity of treatment approaches and the problems
with data are reflected in treatment reviews [25] and treat-
ment guidelines [12].
First generation (typical) antipsychotics (FGAs) were used
since the 50 s, especially for the treatment of acute mania.
However the anecdotal clinical impression many psychia-
trists have is that they induce depression. This was recently
supported by two studies [26,27].
Atypical second generation antipsychotics (SGAs) appear
to have broadly similar efficacy as FGAs against the manic
symptoms of bipolar disorder, but there are important
differences in their tolerability profiles, which are likely to
be of particular relevance during long-term treatment
[24]. Almost all have received regulatory approval for use
in mania, including aripiprazole [28]. If the patient has a
life history of predominant manic or mixed episodes with
rare and short depressive episodes, the administration of
an SGA alone could be enough to control the disorder
[29]. Some SGAs seem to also be effective against acute
bipolar depression and SGAs in general do not seem to
induce switching towards the depressive pole. The biggest
problem with some SGAs is weight gain, hyperlipidaemia
and diabetes in a significant percentage of the patients
receiving them. Various strategies have been developed to
cope with this problem, with varying results so far.
The current article attempts to summarise the data availa-
ble on the usefulness of aripiprazole, which is virtually a
third generation antipsychotic (TGA), and a partial
dopamine agonist.
Methods
A systematic Medline and repositories search of clinical
trials.gov, Cochran collaboration and industry web sites
concerning the usefulness of aripiprazole in bipolar disor-
der was performed, with the combination of the words
'aripiprazole' and 'bipolar'. A selective review was also
performed to locate papers with information directly or
indirectly related to the use of aripiprazole in bipolar dis-
order.
Results
The search returned 184 articles for randomised control-
led trials (RCTs) and was last updated in 15 April 2009.
An additional search included repositories of clinical trials
and previous systematic reviews in order to trace unpub-
lished trials in particular. There were four RCTs comparing
aripiprazole to placebo in acute mania (one unpublished
and one without results), three placebo-controlled com-
parisons to lithium (one) and haloperidol (two) in acute
mania, one RCT of intramuscular aripiprazole in acute
manic agitation, two placebo-controlled RCTs against
bipolar depression, one placebo-controlled RCT and two
placebo-controlled RCTs comparing aripiprazole to
haloperidol and lithium in maintenance and one pla-
cebo-controlled adjunctive aripiprazole to lithium or val-
proate against acute mania (Table 1).
Basic facts about aripiprazole
Aripiprazole (7-(4-[4-(2,3-dichlorophenyl)-1-piperazi-
nyl]butyloxy)-3,4-dihydro-2 (1H)-quinolinone (OPC-
14597), is a derivative of the dopamine autoreceptor ago-
nist 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)-
2(1H)-quinolinone (OPC-4392) [30,31], and was devel-
oped by Otsuka Ltd in Tokyo, Japan and was first
approved by the US FDA in 2002 for the treatment of
schizophrenia. Recently it received approval for the treat-
ment of acute manic and mixed in patients with bipolar I
disorder and for the maintenance treatment of bipolar
patients with a recent manic or mixed episode who had
been stabilised and then maintained for at least 6 weeks.
It is also approved as an adjunct agent for the treatment of
depression.
The mechanism of action of aripiprazole differs both from
FGAs as well as from SGAs, and it seems to be a dopamine
D2 partial and selective agonist [32]. This gives aripipra-
zole the privilege to be considered as the first of a new
group of antipsychotic agents, the TGAs (or dopamine sta-
bilisers or dopamine partial agonists) [33,34].
More specifically, aripiprazole seems to exhibit typical
antagonism at D2 receptors in the mesolimbic pathway,
as well as having unique partial agonist activity at D2
receptors in the mesocortical pathway [35]. Whether it is
an agonist or antagonist depends mainly on the environ-
ment [36,37]. The occupancy at D2 and D3 receptors is
high (from 71% at 2 mg/day to 96% at 40 mg/day) [38-
41]. However although there seems to be a high occu-
pancy of D3 receptors [42] with some observable effects at
least in vitro [38], suggesting an indirect effect on D2 via
D3 [43], their role concerning the clinical effects of arip-
iprazole is disputed [44,45]. Short-term clinical trialsA
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Table 1: Randomised controlled trials (RCTs) assessing the usefulness of aripiprazole in bipolar disorder
Patients (n)
Trial no. Publication Target Duration Comparator Placebo Add on Agent Comparator Placebo Comments
CN138-009 Keck et al., 2003 
[68]
Mania 3 weeks No Yes No 130 132 Agent > placebo
CN138-074/
NCT00036101
Sachs et al., 2006 
[69]
Mania 3 weeks No Yes No 137 135 Agent > placebo
CN138-135/
NCT00095511
Keck et al., 2009 
[70]
Mania 12 weeks Lithium Yes No 155 160 165 Agent = comparator > placebo
CN138-162/
NCT00097266
Young et al., 2009 
[71]
Mania 12 weeks Haloperidol Yes No 167 165 153 Agent = comparator > placebo
CN138-007 unpublished Mania 3 weeks No Yes No 267 134 Agent = placebo
CN138-013 Zimbroff et al., 
2007 [74]
Mania 24 h Lorazepam Yes No 156 70 75 Agent = comparator > placebo
CN138-077/
NCT00046384
Unpublished Mania 3 weeks No Yes No 29 27 No results
CN138008 Vieta et al., 2005 
[72]
Mania 12 weeks Haloperidol No No 175 172 Agent > comparator
CN138-134/
NCT00257972
Vieta et al., 2008 
[73]
Mania 6 weeks No Yes Lithium/Vpx 253 131 Agent > placebo
CN138-096/
NCT00080314
Thase et al., 2008 
[75]
Bipolar 
depression
8 weeks No Yes No 186 188 Agent = placebo
CN138-146/
NCT00094432
Thase et al., 2008 
[75]
Bipolar 
depression
8 weeks No Yes No 187 188 Agent = placebo
CN138-010/
NCT00036348
Keck et al., 2006/7 
[76,77]; Muzina et 
al., 2008 [78]
Maintenance 26 to 100 
weeks
No Yes No 77 83 Agent > placebo
CN138008 Unpublished Maintenance 14 weeks Haloperidol No No 30 9 No results
CN138-135/
NCT00095511
Unpublished Maintenance 40 weeks Lithium No No 56 38 Agent = comparator
Vpx: ValproexAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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reported a very low incidence of extrapyramidal symp-
toms, with akathisia being the most common [46]. Bridg-
ing the above, imaging studies reported that aripiprazole
occupies up to 95% of striatal D2-like dopamine receptors
at clinical doses, and at the same time the incidence of
extrapyramidal side effects is no higher than with placebo
[39,47]. Because of this special mechanism of function,
aripiprazole does not cause upregulation of D2 receptors
or an increase in expression of the c-fos mRNA in the stria-
tum, thus having a low risk for extrapyramidal side effects
(EPS) [48].
There was some concern that presynaptic dopamine
autoreceptor agonists (in spite of being efficacious in the
treatment of psychosis) might potentially increase the risk
for exacerbation of psychosis through stimulation of post-
synaptic dopaminergic receptors. However, the unique
issue with aripiprazole is that it acts as a presynaptic D2
agonist and simultaneously has an antagonistic effect at
the postsynaptic D2 receptors [48]. It is very interesting
that there is evidence that aripiprazole increases
dopamine activity in the frontal cortex [49]. While most
SGAs bind preferentially to extrastriatal receptors, arip-
iprazole has high binding rates throughout the brain.
Aripiprazole is also a partial agonist at the 5-hydroxtryp-
tamine (5-HT)1A receptor [50,51], and an antagonist at
the 5-HT2A receptor [34,52-54] It has moderate affinity
for histamine and α-adrenergic receptors and for the sero-
tonin transporter, and no significant affinity for choliner-
gic muscarinic receptors [52,55-57]. Recent studies have
questioned the role of the 5-HT-mediated systems in the
mechanism of action of aripiprazole [33].
Aripiprazole reaches peak concentration (Cmax) 3 to 5 h
after ingestion, and has a bioavailability of 87% and half
life of 75 h. [58]. It exhibits linear pharmacokinetics and
it is administered once daily [59]. Steady-state plasma
concentrations are achieved after 2 weeks.
It undergoes extensive hepatic metabolisation (dehydro-
genation, hydroxylation, and N-dealkylation), mainly by
cytochrome P450 2D6 (CYP2D6) and cytochrome P450
3A4 (CYP3A4) [60]. The parenteral drug is excreted only
in traces. There is only a minor effect of hepatic or renal
failure on the pharmacokinetics of aripiprazole and no
adjustment of dosage is recommended [61]. There is only
one active metabolite (dehydroaripiprazole) [62], which
typically accumulates to approximately 40% of the arip-
iprazole concentration [61,63]. Its elimination half life is
about 94 h. All the metabolites, either active or not, are
excreted via faeces and urine.
A multicentre, open-label, sequential-cohort, dose-escala-
tion study that explored the tolerability and pharmacoki-
netics of aripiprazole up to 30 mg/day in 21 children and
adolescents (aged 10 to 17 years), preferentially with pri-
mary psychiatric diagnoses of a bipolar or schizophrenia
spectrum disorder, reported that aripiprazole treatment
was generally well tolerated with criteria for tolerability
met for all doses tested. There were no serious side effects,
deaths or clinically relevant changes in vital signs or
weight, and aripiprazole pharmacokinetics seemed to be
linear across the tested dose range [64].
Since aripiprazole is metabolised by CYP2D6 and
CYP3A4, the coadministration with medications that
inhibit (for example, paroxetine, fluoxetine) or induce
(for example, carbamazepine) these metabolic enzymes
alters its plasma levels. Concomitant alcohol use could
lead to an increase of the sedative effects and decrease of
the euphoric effects of alcohol [65], but the latter has not
been replicated [66].
The common side effects during aripiprazole treatment
include akathisia, tremor, headache, dizziness, somno-
lence, sedation fatigue, nausea, vomiting, dyspepsia, con-
stipation, light-headedness, insomnia, restlessness,
sleepiness, anxiety, hypersalivation and blurred vision.
The uncommon side effects, and those whose frequency is
not precisely known, include uncontrollable twitching or
jerking movements, seizures, weight gain, orthostatic
hypotension or tachycardia, allergic reaction (such as
swelling in the mouth or throat, itching, rash), speech dis-
order, agitation, fainting, transaminasaemia, pancreatitis,
muscle pain, stiffness, or cramps and very rarely neurolep-
tic malignant syndrome and tardive dyskinaesia. Elderly
patients with psychosis associated with Alzheimer's dis-
ease and treated with aripiprazole are at increased risk of
death compared to placebo due to cardiovascular (for
example, heart failure, sudden death) or infectious (for
example, pneumonia) problems or stroke.
It is interesting that the investigation of the effect of arip-
iprazole (2.0 to 8.0 mg/kg, orally) vs olanzapine (1.0 to
10 mg/kg, orally) on bodyweight in an animal model in
two strains (Wistar and Sprague-Dawley) and under two
housing conditions (single and group housed) revealed
that subchronic aripiprazole treatment resulted in rapid
and robust weight gain similar to those observed with
olanzapine. In spite of similar effects on bodyweight, arip-
iprazole and olanzapine stimulated markedly different
patterns of prolactin secretion. Bodyweight changes and
prolactin secretion induced by these antipsychotics were
significantly modulated by housing and by strain [67].
Aripiprazole in bipolar disorder
RCTs
Acute mania
Aripiprazole was studied against acute mania in five RCT
studies involving a placebo arm. In the first (CN138-009),
which was published in 2003 [68], 262 patients with aAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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manic or mixed episode, randomised 1:1 to aripiprazole
or placebo, took part. The study duration was 3 weeks and
the mean aripiprazole dosage utilised was 27.9 mg daily,
with 86% of patients receiving the maximum dosage of 30
mg daily. The use of lorazepam was similar in both
groups. Overall, 82 (31%) completed the 3-week trial
duration and the completion rate was higher for aripipra-
zole in comparison to placebo (42% vs 21%, P < 0.001).
Aripiprazole significantly reduced the Young Mania Rat-
ing Scale (YMRS) score by more in comparison to placebo
(-8.2 vs -3.4, P = 0.002) and the Clinical Global Impres-
sion (CGI) score for mania (-1.0 vs -0.4, P  = 0.001),
depression (-0.2 vs +0.1.4, P = 0.03), and overall bipolar
illness (-1.0 vs -0.4, P = 0.001). These data are indirectly
suggestive of an effect on mixed episodes as well. The ther-
apeutic effect was evident from day 4. The response rate
was significantly higher in the aripiprazole group in com-
parison to placebo at endpoint (40% vs 19%). Headache
was the most frequent adverse event, but levels were sim-
ilar in both groups (36% vs 31%). The following events
were more frequent in the aripiprazole group: nausea
(23% vs 10%), dyspepsia (22% vs 10%), somnolence
(20% vs 5%), anxiety (18% vs 10%), vomiting (16% vs
5%), insomnia (15% vs 9%), light-headedness (14% vs
8%), constipation (13% vs 6%), accidental injury (12% vs
2%) and akathisia (11% vs 2%). Two patients with arip-
iprazole had an increase in bodyweight of more than 7%
versus none in the placebo group. Only 11% in the arip-
iprazole group had high prolactin levels at endpoint in
comparison to 17% in the placebo group, while at base-
line the respective values were 30% and 23%.
The second placebo-controlled RCT (CN138-074/
NCT00036101) [69] was published in 2006 and it
included 272 patients with a manic or mixed episode, ran-
domised 1:1 to aripiprazole or placebo and lasted for 3
weeks. The mean aripiprazole dosage utilised was 27.7 mg
daily, with 85% of patients receiving the maximum dos-
age of 30 mg daily. The use of lorazepam was again similar
in both groups. Overall, 145 (53%) completed the 3-week
trial duration and the completion rate was similar for
both study groups (55% vs 52%). Aripiprazole signifi-
cantly reduced the YMRS score by more in comparison to
placebo (-12.5 vs -7.2, P < 0.001) and the CGI score for
mania (-1.59 vs -1.12, P < 0.01), depression (-0.60 vs -
0.31, P < 0.05), and overall bipolar illness (-1.42 vs -0.97,
P < 0.01). The separate analysis of patients with rapid
cycling suggested that aripiprazole significantly reduced
the YMRS score in this group (-15.27 vs -5.45, P = 0.002)
but not the Montgomery Åsberg Depression Rating Scale
(MADRS) score. The same analysis concerning the
patients with mixed episodes revealed a significant effect
on both the YMRS score (-14.12 vs -9.02, P = 0.01) and
the MADRS score (-7.93 vs -4.29, P = 0.041). All therapeu-
tic effects on the total sample and the subgroups of rapid
cycling and mixed episodes patients were all evident from
day 4. The response rate was significantly higher in the
aripiprazole group in comparison to placebo at endpoint
(53% vs 32%). Headache was the most frequent adverse
event, but similar in both groups (25% vs 24.8%). Similar
rates were also registered for anxiety (10.3% vs 8.3%) and
light-headedness (8.8% vs 10.5%). The following events
were more frequent in the aripiprazole group: nausea
(21.3% vs 15.8%), dyspepsia (15.4% vs 6.8%), somno-
lence (19.9% vs 10.5%), vomiting (11% vs 7.5%), consti-
pation (11.8% vs 5.3%) and akathisia (17.6% vs 4.5%).
One patient with aripiprazole had an increase in body-
weight of more than 7% versus five in the placebo group.
Only 4% in the aripiprazole group had high prolactin lev-
els at endpoint in comparison to 11% in the placebo
group.
The third placebo-controlled RCT (CN138-135/
NCT00095511) [70] was published in 2008 and com-
pared aripiprazole to lithium and placebo for 3 weeks and
aripiprazole and lithium for an additional 9 weeks. It
included 480 patients with a manic or mixed episode, ran-
domised 1:1:1 to aripiprazole lithium or placebo for 3
weeks and those on placebo were afterwards randomised
1:1 to either lithium or aripiprazole. Rapid cycling
patients were excluded from the study. The mean aripipra-
zole dosage was 23.2 mg daily at the end of week 3 and
23.6 mg daily at week 12. The respective dosages for lith-
ium were 1,146.9 mg and 1,210.6 mg daily, correspond-
ing to serum levels of 0.76 mEq/litre and 0.66 mEq/litre,
respectively. The use of anxiolytics was similar in all
groups (87.2% to 91.6%). Overall, 229 (47.7%) com-
pleted the 3-week trial duration and the completion rate
was similar for all study groups (placebo 47%, aripipra-
zole 47%, lithium 49%). At week 12 there were 143
patients (30%) still in the study (placebo 28.5%, aripipra-
zole 27%, lithium 33.7%). Aripiprazole and lithium sig-
nificantly reduced the YMRS score by more in comparison
to placebo at week 3 (-12.6 and -12.0, respectively vs -9.0
for placebo, P < 0.001) and this effect was maintained at
week 12 (-14.5 and -12.7, respectively). There was a signif-
icant change in the CGI score for mania (placebo 3.1 vs
lithium 2.9 vs aripiprazole 2.5, P < 0.01 between placebo
and aripiprazole). There were no differences in the
MADRS change among groups, while there were some dif-
ferences in the Positive and Negative Syndrome Scale
(PANSS) subscores between aripiprazole and placebo
(total PANSS, cognitive and hostility subscales). The ther-
apeutic effect was evident from day 2. On the basis of the
YMRS change, the effect size Cohen d was equal to 0.30.
The response rate was significantly higher in the aripipra-
zole and lithium group in comparison to placebo at week
3 (46.8% vs 45.8% vs 34.4%, respectively) and at week 12
there was a slight superiority for aripiprazole in compari-
son to lithium (56.5% vs 49%, respectively). The remis-Annals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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sion rates followed a similar pattern both at week 3
(40.3% vs 40.0% vs 28.2%, respectively) and at week 12
there was again superiority for aripiprazole in comparison
to lithium (49.4% vs 39.4%, respectively). Headache was
the most frequent adverse event, but similar in all groups
(placebo 22.6%, lithium 20.1%, aripiprazole 23.4%). The
following events were more frequent in the aripiprazole
group: nausea (13.4% vs 23.3% vs 22.7%), constipation
(6.1% vs 10.73% vs 10.4%), sedation (4.9% vs 6.9% vs
11.7%), tremor (4.9% vs 10.1% vs 7.1%), and akathisia
(3.0% vs 5.0% vs 11.0%). One patient with aripiprazole,
one on placebo and two on lithium had an increase in
bodyweight of more than 7%. Only 8.2% in the aripipra-
zole group had high prolactin levels at week 12 in com-
parison to 18.2% in the lithium group.
The fourth placebo-controlled RCT (CN138-162/
NCT00097266) [71] was published in 2009 and com-
pared aripiprazole to haloperidol and placebo for 3 weeks
and aripiprazole and lithium for an additional 9 weeks. It
included 485 patients with a manic or mixed episode, ran-
domised 1:1:1 to aripiprazole haloperidol or placebo for
3 weeks and those on placebo were afterwards put blindly
on aripiprazole. Rapid cycling patients were excluded
from the study. The mean aripiprazole dosage was 23.6
mg daily at the end of week 3 and 22 mg daily at week 12.
The respective daily dosages for haloperidol were 8.5 and
7.4 mg daily. At the end of week 3, 53% of aripiprazole
treated patients were receiving 30 mg daily and at week 12
the percentage was 48%. The use of concomitant psycho-
active medication was similar in all groups (66% to 77%).
Overall, 356 (73.4%) completed the 3-week trial duration
and the completion rate was similar for all study groups
(placebo 71%, aripiprazole 75%, haloperidol 73%). At
week 12 there were 274 patients (56.5%) still in the study
(placebo 55%, aripiprazole 57%, haloperidol (58%).
Aripiprazole and haloperidol significantly reduced the
YMRS score by more in comparison to placebo at week 3
(-11.9 and -12.8, respectively vs -8.7 for placebo, P < 0.05)
and this effect was maintained at week 12 (-17.2 and -
17.8, respectively). There was a significant change in the
CGI score for mania (placebo -1.1 vs haloperidol -1.5 vs
aripiprazole -1.4, P < 0.05). There were no differences in
the MADRS change among groups, while there were some
differences in the PANSS subscores between aripiprazole
and placebo (total PANSS, positive, cognitive and hostil-
ity subscales). The therapeutic effect was evident from day
2. The response rate was significantly higher in the arip-
iprazole and haloperidol group in comparison to placebo
at 3 weeks (47% vs 49.7% vs 38.2%, respectively) and at
12 weeks there was a similar rate of response for aripipra-
zole and haloperidol (72.3% vs 73.9%, respectively). The
remission rates followed a similar pattern both at 3 weeks
(44% vs 45.3% vs 36.8%, respectively) and at 12 weeks
there was again a similarity of rates between aripiprazole
and haloperidol (69.9% vs 71.4%, respectively). The fol-
lowing events were frequent in the aripiprazole group:
insomnia (13.9%), EPS (7.8%), and akathisia (11.4%). At
week 3, there were three patients on aripiprazole, nine on
placebo and four on haloperidol that had an increase in
bodyweight of more than 7%. At the same time point,
22.4% on aripiprazole vs 66.2% on haloperidole had high
prolactin levels and at week 12 the respective percentages
were 12.8% and 60.8%.
A fifth trial, (CN138-007) was negative and was not pub-
lished [28]. It included 267 patients randomised to fixed
doses of aripiprazole (131 patients to 15 mg daily and 136
to 30 mg daily) and 134 to placebo for 3 weeks. Total dis-
continuation was similar in all groups (57% to 60%) and
the reasons for discontinuation were also similar. The
changes in the YMRS score were -10.01, -10.8 and -10.12,
respectively. The CGI changes were 4.66, 4.7 and 4.68,
respectively and the PANSS changes were again similar.
The sixth trial (CN138-077/NCT00046384) did not pro-
duce any results due to the small number of patients
recruited (29 in the aripiprazole arm and 27 in the pla-
cebo arm).
In a 12-week RCT (CN138008) of aripiprazole compari-
son to haloperidol (in a 1:1 ratio. without a placebo arm),
in 347 patients with bipolar I disorder experiencing acute
manic or mixed episodes (175 in the aripiprazole group
and 172 in the haloperidol group), at week 3, the average
daily dosage of aripiprazole was 22.6 mg and of haloperi-
dol was 11.6 mg. At week 12, average daily dosages were
21.6 mg for aripiprazole and 11.1 mg for haloperidol. No
psychotropic medications including anticholinergics were
permitted, except for benzodiazepines during the first few
days. Overall, 134 patients receiving aripiprazole and 95
receiving haloperidol completed the first 3 weeks of treat-
ment; the week 12 numbers were 89 and 50, respectively.
The response rate was 49.7% in the aripiprazole group
and 28.4% in the haloperidol group (P < 0.001). The pro-
portion of patients in remission at week 12 was signifi-
cantly higher in the aripiprazole group than in the
haloperidol group (50% v. 27%; P = 0.001). The efficacy
measures showed similar changes in the aripiprazole and
haloperidol groups with both last observation carried for-
ward and observed cases analyses. Significantly more
patients demonstrated a 50% or greater decrease in
MADRS total score from baseline with aripiprazole than
with haloperidol at week 12 (51% v. 33%; P = 0.001) and
aripiprazole treatment produced greater numerical reduc-
tions in depressive symptoms compared with haloperi-
dol, as measured by the mean change in MADRS total
score at endpoint. Of 173 patients treated with aripipra-
zole, 19 (11.0%) switched to depression; of 164 on
haloperidol, 29 (17.7%) switched to depression. TheAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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most frequent adverse events leading to discontinuation
were extrapyramidal symptoms (haloperidol 18.9% vs
aripiprazole, 2.9%), and akathisia (haloperidol 14.2% vs
aripiprazole 5.1%). During the study, time to discontinu-
ation for any reason was significantly greater for patients
receiving aripiprazole than those receiving haloperidol (P
= 0.001). The most common reason for discontinuation
was experiencing adverse events which showed a marked
difference in incidence between the groups (aripiprazole
9.7% vs haloperidol 30.8%). The incidence of extrapy-
ramidal adverse events in the haloperidol group (62.7%)
was more than double that in the aripiprazole group
(24.0%), while the mean change in weight from baseline
at endpoint was not significantly different between
groups. Serum prolactin levels showed a mean decrease
from baseline in the aripiprazole group (-13.4 ng/ml, -
284.1 mU/litre), and a mean increase in the haloperidol
group (7.7 ng/ml, 163.2 mU/litre) at week 12 (P = 0.001).
In the haloperidol group, 57.1% of patients experienced
serum prolactin levels above the upper limit of normal
compared with 14.1% in the aripiprazole group. No clin-
ically meaningful difference was detected in vital sign
measurements, laboratory abnormalities or cholesterol
levels between the aripiprazole and haloperidol treatment
groups [72].
There was a final 6-week placebo-controlled RCT (CN138-
134/NCT00257972) with aripiprazole as adjunctive treat-
ment to lithium or valproate [73]. It included 131 patients
in the placebo arm and 253 in the aripiprazole arm; 157
were receiving lithium and 227 were receiving valproate.
Double-blind treatment was completed by 85% and 79%
of patients randomly assigned to placebo and aripipra-
zole, respectively. Discontinuation rates due to adverse
events were higher for patients in the aripiprazole group
than for patients in the placebo group (9% vs 5%). The
mean dose of aripiprazole during week 6 was 19.0 mg/
day. The dosages of lithium and valproate treatment were
similar in the placebo and the aripiprazole groups (lith-
ium 994 mg/day and 1,119 mg/day, serum levels 0.77
mmol/litre and 0.78 mmol/litre, respectively; valproate
1,175 mg/day and 1,180 mg/day, respectively). At end-
point, adjunctive aripiprazole showed significantly
greater improvements from baseline in YMRS total score
than placebo (-13.3 ± 7.9 vs -10.7 ± 7.6, P < 0.0) but this
was due to the valproate but not the lithium group. At
endpoint the remission rate was 66.0% for aripiprazole
and 50.8% for placebo (P < 0.01, number needed to treat
(NNT) = 7). The improvement over placebo in MADRS
was not statistically significant at endpoint, however the
proportion of patients with emergent depression was sig-
nificantly lower in the aripiprazole arm than the placebo
arm (7.7% vs 16.9%; P  < 0.01). The most frequently
reported adverse event was akathisia (aripiprazole: 18.6%
vs placebo: 5.4%), tremor (placebo: 6.2% vs aripiprazole:
9.1%), EPS (placebo: 0.8% vs aripiprazole: 4.7%), hyper-
tonia (placebo: 0% vs aripiprazole: 0.4%), hypokinaesia
(placebo: 0% vs aripiprazole: 0.4%), muscle spasms (pla-
cebo: 0.8% vs aripiprazole: 2.0%), dyskinaesia (placebo:
0.8% vs aripiprazole: 0.4%) and muscle twitching (pla-
cebo: 0% vs aripiprazole: 0.4%). The lithium subgroup
showed higher rates of akathisia (aripiprazole: 28.3% vs
placebo: 4.0%) and tremor (aripiprazole: 13.2% vs pla-
cebo: 8.0%) than the valproate subgroup (aripiprazole:
11.6% vs placebo: 6.3% and aripiprazole: 6.1% vs pla-
cebo: 5.0%, respectively). There were no clinically mean-
ingful differences between treatments in weight change
and laboratory parameters including serum prolactin lev-
els and electrocardiogram (ECG).
The above studies strongly support the efficacy of aripipra-
zole against acute mania and they report that the separa-
tion from placebo occurred as early as days 2 to 4. They
also provide some support for its efficacy against mixed
episodes and rapid cycling without switching to depres-
sion. Side effects included mainly akathisia, without
weight gain, hyperprolactinaemia or corrected QT (QTc)
prolongation.
A placebo-controlled RCT was conducted on the efficacy
and safety of intramuscular aripiprazole for the treatment
of agitation in patients with bipolar I disorder, manic or
mixed episodes [74], which included 301 patients of
whom 78 were randomised to intramuscular aripiprazole
9.75 mg per injection, 78 to 15 mg per injection, 70 to
intramuscular lorazepam 2 mg per injection and 75 to
intramuscular placebo. The mean improvements in
PANSS-Excited component score at 2 h were significantly
greater with aripiprazole (-8.7 for the 9.75 mg group and
-8.7 for the 15 mg group) and lorazepam (-9.6) versus pla-
cebo (-5.8), with P < 0.001. Also for all other efficacy
measures, all three active treatments were similar and
superior to placebo at 2 h (P < 0.05).
Acute bipolar depression
There are two 8-week placebo-controlled RCTs concerning
the use of aripiprazole in acute bipolar depression (non-
psychotic bipolar I patients) and they were both negative
at study endpoint [75].
The CN138-096/NCT00080314 included 374 patients;
188 on placebo and 186 on aripiprazole (5 to 30 mg
daily). More patients in the aripiprazole group (47%) dis-
continued double-blind treatment than in the placebo
group (35%). The mean aripiprazole dose at the end of
the study was 17.6 mg daily. The results suggest that in
weeks 1 to 6 there was a significant reduction in the
MADRS scores in the aripiprazole group in comparison to
placebo (-4.55 vs -6.61; -7.55 vs -9.61; -8.88 vs -11.06; -
9.7 vs -12.28; -10.54 vs -13.24; -9.98 vs -12.66 for weeks 1Annals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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to 6, respectively), but at week 7 this difference disap-
peared (-11.14 vs -11.86) and eventually the active agent
was no better than placebo. Hypnotics and sedatives were
used by 25% of aripiprazole patients and 21% of placebo
patients. At least 1 adverse event was reported by 142
(76%) of the 186 patients in the placebo group and 154
(87%) of the 178 patients in the aripiprazole group. The
most frequent adverse events (≥5% incidence in the arip-
iprazole group and twice the incidence in the placebo
group) were akathisia (28%), insomnia (16%), nausea
(15%), fatigue (11%), back pain (8%), dry mouth (8%),
increased appetite (7%), vomiting (6%), anxiety (6%),
and sedation (5%). One suicide attempt occurred in the
placebo group and one patient in the aripiprazole group
manifested severe suicidal ideation. In addition, three
non-serious suicidal ideation events were reported in the
aripiprazole group. EPS-related adverse events occurred in
18 (9.7%) of placebo-treated patients and 61 (34.3%) of
aripiprazole-treated patients. Of the EPS-related adverse
events, only akathisia was reported at a frequency of ≥10%
in the aripiprazole group and at least twice the rate of pla-
cebo.
The CN138-146/NCT00094432 included 375 patients;
188 on placebo and 187 on aripiprazole (5 to 30 mg
daily). More patients in the aripiprazole group (41.2%)
discontinued double-blind treatment than in the placebo
group (29.8%). The mean aripiprazole dose at the end of
the study was 15.5 mg daily. The results suggest that in
weeks 1 to 3 and then again at week 5 there is a significant
reduction in the MADRS scores in the aripiprazole group
in comparison to placebo (-4.97 vs -6.54; -6.75 vs -9.52; -
9.26 vs -11.65 and -10.47 vs -13.33, for weeks 1 to 3 and
5, respectively), but at endpoint this difference disap-
peared (-11.46 vs -12.34) and eventually the active agent
was no better than placebo. Hypnotics and sedatives were
used by 24% of aripiprazole patients and 17% of placebo
patients. At least 1 adverse event was reported by 132
(72.9%) of the 181 patients in the placebo group and 155
(85.2%) of the 182 patients in the aripiprazole group. The
most frequent adverse events (≥5% incidence in the arip-
iprazole group and at least twice the incidence in the pla-
cebo group) were akathisia (21.4%), restlessness (12.1%),
anxiety (9.3%), disturbance in attention (5.5%), and
sedation (5.5%). One suicide attempt occurred in the pla-
cebo group and one severe adverse event of suicidal idea-
tion occurred in the aripiprazole group. EPS occurred in
19 (10.5%) of placebo-treated patients and 54 (29.7%) of
aripiprazole-treated patients. Of the EPS-related adverse
events, only akathisia was reported at a frequency of ≥10%
in the aripiprazole group and at least twice the rate of pla-
cebo.
There were no clinically relevant changes in weight gain,
serum prolactin from baseline to endpoint and no differ-
ences between the two treatment groups in potentially
clinically relevant vital sign or ECG abnormalities. The
higher discontinuation rates in the aripiprazole group
than in the placebo group in both studies demonstrate
that the dosing regimen of aripiprazole (5 to 30 mg/day)
was not as well tolerated in this patient population as
were the dosing regimens used in previous studies in
patients with bipolar mania or schizophrenia.
Maintenance phase
There was one placebo-controlled RCT (CN138-010/
NCT00036348) studying aripiprazole in the maintenance
phase in bipolar I, recently manic patients [76]. Patients
were stabilised with 15 to 30 mg of aripiprazole for 6 to
18 weeks and then randomised to a 1:1 ratio to aripipra-
zole or placebo for an additional 26 weeks. Only anti-
cholinergics and lorazepam were allowed as concomitant
medication. During the 26 weeks 71.1% of patients on
placebo and 71.4% of patients on aripiprazole received at
least one concomitant medication. The primary efficacy
outcome was time to relapse for a mood episode. From a
total of 633 patients initially screened and 206 of them
who completed the stabilisation phase, 161 were ran-
domised (83 to placebo and 78 to aripiprazole). A total of
39 patients (50%) on aripiprazole and 28 (34%) on pla-
cebo completed the 26 weeks of the trial. The mean arip-
iprazole daily dosage at the end of 26 weeks was 24.3 mg.
The time to relapse was significantly longer for aripipra-
zole (P = 0.02) and the hazard ratio (HR) was 0.52. This
was due to a prolongation in the time to relapse to a
manic (P = 0.01, HR = 0.31) but not to a depressive epi-
sode. Unfortunately the mean time to relapse for either
group was not reported. At the end of the study 49% of the
placebo group and 72% of the aripiprazole group had not
experienced a relapse to a mood episode. The difference
was significant only concerning manic relapses (23% vs
8%; P = 0.009). The same was true for the final YMRS
score while there was no difference concerning the
MADRS score. There was also a superiority of aripiprazole
in comparison to placebo concerning the CGI and the
PANSS scores.
More patients with a current episode of mania were ran-
domly assigned to placebo (78%) in comparison to arip-
iprazole (62%), and fewer with mixed episode were
randomised to placebo (22%) than to aripiprazole
(38%). This means the aripiprazole group had more
patients with mixed index episodes, and thus might con-
stitute a more refractory group of patients, especially with
respect to the depressive aspect of symptomatology. The
adverse events reported by aripiprazole-treated patients at
an incidence ≥5% and twice the incidence of placebo dur-
ing the maintenance phase were tremor (9.1%), akathisia
(6.5%), vaginitis (6.4%), and pain in the extremities
(5.2%). One aripiprazole-treated patient and one pla-Annals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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cebo-treated patient attempted suicide in the stabilisation
and maintenance phases, respectively. There were no sig-
nificant differences concerning the QTc, while aripipra-
zole treated patients showed a significant drop in
prolactin levels. Concerning weight gain, 13% of aripipra-
zole treated patients put >7% of weight in comparison to
none in the placebo group.
This same trial (CN138-010/NCT00036348) also
included a 74-week placebo-controlled extension phase
[77], which included 66 of the 67 patients who completed
the 26-week period. Unfortunately only 12 of them (5 in
the placebo group and 7 in the aripiprazole group) com-
pleted the 74-week treatment period. The reasons for this
high discontinuation rate varied and included lack of effi-
cacy, side effects (very low percentage) and most impor-
tantly the very design and structure of the study (the study
was closed by the sponsor when the prespecified number
of relapses had been attained). Because of this and
because detailed descriptive data were not reported, arriv-
ing at conclusions is very difficult. The mean dosage of
aripiprazole at the end of the 74-week period was 23.6 mg
daily. It is reported that 29 out of the 66 patients relapsed
(16 out of the 39 in the aripiprazole group (41%) and 13
out of the 27 in the placebo group (48.1%)). The only dif-
ference concerned manic relapses (nine in the placebo
and six in the aripiprazole group). Again the YMRS score
significantly differed between groups. The adverse events
had a similar rate to the 26-week period.
In both the above reports the median survival time for the
aripiprazole group was not evaluable, while the median
survival time for placebo was 118 to 203 days depending
on the clinical subpopulation [78].
A post hoc subgroup analysis [78] of 28 patients (14 on
placebo and 14 on aripiprazole) with rapid-cycling bipo-
lar I disorder from the previous maintenance study
(CN138-010/NCT00036348) suggested that aripiprazole
was more effective than placebo in the prophylaxis of
rapid cycling patients against manic/mixed episodes.
More specifically, 12 patients (5 on placebo (36%) and 7
on aripiprazole (50%)) completed the 26-week period,
and 3 completed the 100-week period (none on placebo
(0%), 3 on aripiprazole (21%)). The mean endpoint arip-
iprazole daily dosage was 25.3 mg for the 26-week phase
and 23.6 for the 100-week phase. The time to relapse was
significantly longer with aripiprazole vs placebo treat-
ment at both 26 weeks (P = 0.033; HR = 0.21) and 100
weeks (P = 0.017; HR = 0.18). The median survival time
in the placebo group was 118 days at which time approx-
imately 45% of patients had not yet relapsed. The median
survival time for the aripiprazole group was not evaluable.
At the time of the last relapse event in the study period,
which occurred at day 101, 81% of aripiprazole-treated
subjects with rapid-cycling bipolar disorder had not yet
relapsed. The YMRS total scores increased in both groups
and this increase was numerically smaller with aripipra-
zole vs placebo from at week 26 (+3.0 ± 2.0 vs +6.6 ± 2.0;
P = 0.213; effect size 0.506) and week 100 (+2.6 ± 2.6 vs
+9.5 ± 2.6; P = 0.077; effect size 0.730). The same held
true for the MADRS total scores, which increased in both
treatment groups with no statistically significant differ-
ence with aripiprazole versus placebo at week 26 (+8.3 ±
3.3 vs +11.5 ± 3.3; P = 0.519; effect size 0.251) or week
100 (+7.7 ± 3.3 vs +12.5 ± 3.3; P  = 0.304; effect size
0.403).
The extension of the acute phase trial CN138-135/
NCT00095511 [70] for an additional 40 weeks (52 weeks
in total) comparing aripiprazole to lithium without a pla-
cebo arm suggested aripiprazole is equal to lithium in
maintenance against manic episodes. Of the original 480
patients during the acute phase, 94 entered the 40-week
extension phase (38 from the original lithium group, 25
patients from the aripiprazole group and 31 from the orig-
inal placebo group who all switched to aripiprazole). The
mean daily dose of aripiprazole and lithium during the
last 4 weeks of the extension phase were 21.7 mg/day and
1,209.1 mg/day, respectively. A total of 34 of the 94
patients completed the extension phase it; 7 (4.5%)
patients in the aripiprazole group, 13 (8.1%) patients in
the lithium group, and 14 (8.5%) patients who were ran-
domised to placebo and blindly switched to aripiprazole
after week 3. The most frequently occurring treatment-
related adverse events in the aripiprazole treatment group
were akathisia (8.0%) and headache (8.0%) and in the
lithium treatment group was diarrhoea (10.5%). For both
treatment groups, the improvement that was observed at
the end of 12-week double-blind treatment phase was
maintained throughout the extension phase. No clinically
relevant trends were reported in laboratory, vital sign, or
ECG results during long-term treatment of aripiprazole.
Another trial extension, that for trial CN138008 to a fur-
ther 14 weeks, failed to provide any results because of a
high drop-out rate.
Other studies and case reports
There are a number of interesting open trials concerning
the usefulness of aripiprazole in bipolar depression, espe-
cially in refractory cases and also as adjunctive treatment.
A 6-week prospective, non-randomised, open-label study
in 20 bipolar depressed outpatients (10 type I, 7 type II, 3
type not otherwise specified (NOS)), with flexible arip-
iprazole dosage (up to 30 mg daily) reported a response
rate of 44% in patients who completed at least 1 week of
treatment and a drop-out rate of 35% [79]. The assess-
ment of anhedonia in 50 bipolar I patients revealed it wasAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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present in 52% of them and was significantly reduced dur-
ing treatment with aripiprazole. In this study all patients
completed the 16-week trial and 16% of patients experi-
enced side effects (mainly akathisia and headache) [80].
Two open studies examine the response of refractory
bipolar depressive patients to aripiprazole monotherapy.
In the first, aripiprazole response was prospectively
assessed for 8 weeks in 31 patients with acute bipolar
depression inadequately responsive to a mood stabiliser.
Only 45% completed the 8-week trial and discontinua-
tion was primarily due to side effects. The results sug-
gested that 42% patients responded and 35% remitted
[81]. In the second, aripiprazole response was prospec-
tively assessed for 16 weeks in 85 acutely depressed bipo-
lar patients with inadequate responsive to 1 mood
stabiliser. In half of them aripiprazole was given as mon-
otherapy. Only 3.5% of patients discontinued the study
for side effects while 21.2% of patients experienced aka-
thisia. The trial was completed by 94.1% of patients. The
response rate was 65% and the remission rate was 37.5%
[82].
An open clinical trial of adjunctive aripiprazole to 30 out-
patients with treatment-resistant bipolar depression (11
type I, 15 type II, 4 NOS; mean age 44.4 ± 17.0 years, 70%
female) for a mean duration of 84 ± 69 days, and with a
mean final dose of 15.3 ± 11.2 led to a 47% discontinua-
tion (17% due to inefficacy, 10% patient choice and 20%
due to adverse events) and to 27% response including
13% remission [83]. In an open-label study aripiprazole
was coadministered at 10 mg/day for 3 days, 20 mg/day
for 3 days, then 30 mg/day for 8 days, with lamotrigine in
18 bipolar patients. The results suggest aripiprazole has
no meaningful effect on lamotrigine steady-state pharma-
cokinetics in patients with bipolar I disorder [84]. An
open-label 12-week trial of adjunctive aripiprazole (initi-
ated at 5 mg daily and increased as tolerated) to existing
mood stabiliser medication treatment in 20 older adults
(aged 50 to 83 years) reported significant improvement in
both manic and depressive symptoms with good tolera-
bility [85].
There are two chart review studies on the adjunctive use of
aripiprazole in refractory bipolar depressives. The first
suggests that the review of 12 patients with treatment-
resistant bipolar disorder (I, II and NOS) who received
aripiprazole augmentation for the relief of an acute major
depressive episode revealed that after 8 weeks of treatment
33% of patients demonstrated a response but 42% of
patients newly developed akathisia [86] The results were
sustained after 36 months [87]. The second review of
chart records of 10 patients with bipolar I depression
refractory to mood stabilisers and treated with adjunctive
aripiprazole 15 to 30 mg/day for 21 to 110 days suggests
that 70% responded [88].
Aripiprazole has also been studied in the treatment of pae-
diatric bipolar disorder. An 8-week, open-label, prospec-
tive study of aripiprazole 9.4 ± 4.2 mg/day monotherapy
against acute mania in paediatric bipolar disorder in 19
youths reported that 79% completed the study and arip-
iprazole treatment was associated with significant
improvement. There were only two drop out cases due to
extrapyramidal symptoms [89]. Another open 6-week
trial in 10 children and adolescents with acute mania
comorbid with attention-deficit/hyperactivity disorder
(ADHD) reported an improvement in global functioning
scores and ADHD symptoms. However although in gen-
eral tolerability was good, significant weight gain was
observed [90]. A retrospective medical chart review of 30
child and adolescent bipolar patients with a Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) diagnosis of bipolar type I, type II disorder,
NOS, or schizoaffective disorder, bipolar type, and who
were treated with aripiprazole (mean starting dose = 9 ± 4
mg/day, mean final dose = 10 ± 3 mg/day) suggested that
the overall response rate was 67%. No serious adverse
events were identified and the common side effects
included sedation (n = 10, 33%), akathisia (n = 7, 23%),
and gastrointestinal disturbances (n = 2, 7%). The change
in weight ranged from +5 to -21 kg and 86% of patients
lost weight [91]. Another retrospective medical chart
review of 41 youths (mean age ± standard deviation (SD):
11.4 ± 3.5 years) with bipolar spectrum disorder treated
with aripiprazole (mean daily dose of aripiprazole 16.0 ±
7.9 mg over an average of 4.6 months) suggested a
response rate of 71% in manic symptoms and the treat-
ment with aripiprazole was well tolerated [92].
Finally, a study on 20 antipsychotic-treated patients with
bipolar or schizoaffective disorder and current substance
abuse who were switched to open-label aripiprazole over
12 weeks showed an improvement in Hamilton Rating
Scale for Depression (HAM-D) (P = 0.002), YMRS (P =
0.021), Brief Psychiatric Rating Scale (BPRS) (P = 0.000)
scores as well as a decrease in alcohol and substance crav-
ing without a significant change in antipsychotic-induced
side effect scales [93].
A number of case reports provide further information
concerning the effects and the safety of aripiprazole. There
are a limited number of case reports suggesting that tar-
dive dyskinaesia is improved with aripiprazole treatment
[94] and this happens also with haloperidol-induced
hyperprolactinaemia [95]. In contrast, aripiprazole might
lead to neuroleptic malignant syndrome (one case report
in coadministration with lithium) [96]. Aripiprazole can
induce acute dystonia in younger patients with concomi-
tant drug abuse or Tourette's disorder [97-99], and there is
also a case report on a paradoxical motor syndrome fol-
lowing a switch from atypical neuroleptics to aripiprazole
[100] There is one case report in the literature concerningAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
Page 11 of 15
(page number not for citation purposes)
the occurrence of severe extrapyramidal symptoms in an
adolescent with a history of such symptoms [101] and in
a 3-year old child [102]. Specifically, the child weighed
15.5 kg, and adverse events occurred after the accidental
ingestion of a single dose of <15 mg of aripiprazole (prob-
ably half of a 15 mg pill); the patient was hospitalised 48
h later with extreme lethargy, flat affect, intention tremor,
truncal ataxia and Parkinsonian gait (serum levels: 63 ng/
ml 87 h after ingestion). Complete resolution of symp-
toms and signs occurred after 7 days. There is also a single
case report of induction of hyponatraemia [103] and
another of aripiprazole-induced orthostatic hypotension
and cardiac arrhythmia [104]. A very rare side effect is
reported in a case report of a woman who developed
photo-onycholysis on multiple nails after uptake of olan-
zapine and subsequent substitution of olanzapine with
aripiprazole further exacerbated the problem [105].
Discussion
Recent reviews suggest that aripiprazole is efficacious in
acute mania and in the maintenance treatment of bipolar
disorder, with a favourable safety and tolerability profile,
with minimal propensity for clinically significant weight
gain and metabolic disruption. Aripiprazole should be
initiated at 15 mg/day (range 5 to 20 mg/day). If neces-
sary, adjunctive medication should be used in early treat-
ment to manage side effects or assist in management of
symptoms such as agitation. When switching to aripipra-
zole, the therapeutic dose of current treatment should be
maintained while adding aripiprazole 15 (5 to 20) mg/
day. Only once an effective dose of aripiprazole is reached
should previous medication be reduced [106].
A meta-analysis of the two 3-week acute mania RCTs
[68,69] suggests that aripiprazole is effective in all sub-
populations irrespective of the baseline MADRS score and
the presence of rapid cycling, with the exception of remis-
sion in patients over 55 years of age [107]. Another meta-
analysis of these same RCTs suggested that aripiprazole
was superior to placebo in reducing the severity of both
mania and agitation in highly agitated patients with bipo-
lar I disorder and showed significant antimanic activity in
patients with low levels of agitation without increasing
agitation. These findings suggest that aripiprazole's anti-
manic effect is specific and not limited to control of agita-
tion through sedation [108].
Specifically concerning the effectiveness of aripiprazole
against agitation, meta-analytic studies suggest that
although non-sedated patients with bipolar I disorder
showed significant decreases in PANSS-Excited compo-
nent scores following treatment with aripiprazole intra-
muscularly, which is approved for the treatment of
agitation associated with schizophrenia or bipolar I disor-
der (manic or mixed) and this improvement was similar
to that seen in patients with schizophrenia, the latter
showed significant reductions in PANSS-Excited compo-
nent scores compared with placebo regardless of baseline
level of agitation. In contrast, patients with bipolar I dis-
order who had higher baseline agitation showed similar
improvement on either aripiprazole or placebo while
those with lower baseline agitation improved significantly
more on aripiprazole [109,110].
The systematic review and meta-analysis of 13 ran-
domised, placebo-controlled trials (involving 3,089 sub-
jects) in acute bipolar mania, which included two
aripiprazole studies, suggested a response to treatment (at
least 50% reduction in YMRS scores) more than 1.7 times
higher in comparison to placebo (relative risk (RR) = 1.74,
95% confidence interval (CI) 1.54 to 1.96). Small but sig-
nificant increases in extrapyramidal side effects occurred
with risperidone and aripiprazole [111]. Another meta-
analysis on 15 RCTs and 2,022 patients suggests that arip-
iprazole is more effective than haloperidol (which in turn
is more effective than placebo) at reducing manic symp-
toms, both as monotherapy and as adjunctive treatment
to lithium or valproate and equally effective as olanzapine
or risperidone [112]. Another systematic review and meta-
analysis from 12 placebo-controlled monotherapy and 6
placebo-controlled adjunctive therapy trials involving a
total of 4,304 subjects (including 1,750 placebo-treated
subjects) of atypical antipsychotics for acute bipolar
mania reports that aripiprazole, olanzapine, quetiapine,
risperidone, and ziprasidone all demonstrated significant
efficacy in monotherapy without any significant differ-
ences in efficacy among antipsychotics. The magnitude of
improvement was similar whether the antipsychotic was
utilised as monotherapy or adjunctive therapy [113].
Conclusively, the data on the effectiveness of aripiprazole
against acute manic/mixed episodes are strong, and so are
the data concerning the prophylaxis against these epi-
sodes in patients who experienced predominantly manic
episodes and whose manic episodes responded to arip-
iprazole treatment. There are some data suggesting arip-
iprazole is effective in rapid cycling patients. The data
against acute bipolar depression are negative although the
research on lower dosages (5 to 10 mg daily) could be
warranted since aripiprazole initially seemed to provide
positive results in comparison to placebo, which however
did not last. There are significant data for the usefulness of
aripiprazole as adjunctive therapy to lithium or valproate
in refractory bipolar depressive patients. The majority of
trials included patients with moderate to severe manic
episodes, some of whom also had psychotic symptoms.
With regards to safety, aripiprazole was generally reported
to be safe and well tolerated. The adverse effects of arip-
iprazole were generally mild to moderate and similar toAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
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those previously observed in the schizophrenia popula-
tion treated with aripiprazole. It is important that the
adverse effect profile of aripiprazole differs from that of
the SGAs since aripiprazole did not show any safety con-
cerns on QT prolongation, hyperprolactinaemia, or
weight gain. However, EPS such as akathisia was more fre-
quently reported in aripiprazole-treated than in placebo-
treated patients, but at a rate of approximately half that of
haloperidol-treated patients; this could still could be treat-
ment limiting in some cases. The hazard risk for tardive
dyskinaesia with aripiprazole in the bipolar population is
unknown [114,115].
Competing interests
KNF is a member of the International Consultation Board
of Wyeth for desvenlafaxine and has received honoraria
for lectures from AstraZeneca, Servier, Janssen-Cilag, Eli
Lilly and research grants from AstraZeneca, Janssen-Cilag,
Elpen and Pfizer Foundation.
EV has acted as consultant, received grants, or received
honoraria for lectures by the following companies: Almi-
rall, AstraZeneca, Bial, Bristol-Myers-Squibb, Eli Lilly, For-
rest Research Institute, GlaxoSmithKline, Janssen-Cilag,
Jazz Lundbeck, Merck Sharpe Dohme, Novartis, Organon,
Pfizer, Sanofi, Servier and UBC.
Authors' contributions
Both authors independently reviewed the entire literature
and contributed equally to the authoring of the paper
References
1. Lange F: De vigtigste Sindssygdomme (the most important
pychiatric disorders).  Copenhagen, Denmark: Gyldendal; 1894. 
2. Cade J: Lithium salts in the treatment of psychotic excite-
ment.  Med J Aust 1949, 36:349-352.
3. Cade J: The story of lithium.  In Discoveries in biological psychiatry
Edited by: Ayd F, Blackwell B. Philadelphia, PA: Lippincott; 1970. 
4. Bech P: The full story of lithium. A tribute to Mogens Schou
(1918–2005).  Psychother Psychosom 2006, 75:265-269.
5. Schou M, Juel-Nielsen N, Stromgren E, Voldby H: The treatment of
manic psychosis by the administration of lithium salts.  J Neu-
rol Neurosurg Psychiatry 1954, 17:250-260.
6. Schou M: Forty years of lithium treatment.  Arch Gen Psychiatry
1997, 54:9.
7. Baastrup P: The use of lithium in manic-depressive psychosis.
Compr Psychiatry 1964, 5:396-408.
8. Baastrup PC, Schou M: Lithium as a prophylactic agents. Its
effect against recurrent depressions and manic-depressive
psychosis.  Arch Gen Psychiatry 1967, 16:162-172.
9. Schou M, Baastrup PC: Lithium treatment of manic-depressive
disorder. Dosage and control.  JAMA 1967, 201:696-698.
10. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A: Prophy-
lactic lithium: double blind discontinuation in manic-depres-
sive and recurrent-depressive disorders.  Lancet 1970,
2:326-330.
11. Fountoulakis KN, Vieta E, Bouras C, Notaridis G, Giannakopoulos P,
Kaprinis G, Akiskal H: A systematic review of existing data on
long-term lithium therapy: neuroprotective or neurotoxic?
Int J Neuropsychopharmacol 2008, 11:269-287.
12. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea
JM, Kaprinis GS: Treatment guidelines for bipolar disorder: a
critical review.  J Affect Disord 2005, 86:1-10.
13. Moller H, Bottlender R, Grunze H, Streuss A, Wittmann J: Are anti-
depressant less effective in the acute treatment of bipolar I
compared to unipolar depression?  J Affect Disord 2001,
67:141-146.
14. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW,
Suppes T, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J,
Kitchen CMR, Mintz J: Mood switch in bipolar depression: com-
parison of adjunctive venlafaxine, bupropion and sertraline.
Br J Psychiatry 2006, 189:124-131.
15. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE
Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post
RM: Risk of switch in mood polarity to hypomania or mania
in patients with bipolar depression during acute and contin-
uation trials of venlafaxine, sertraline, and bupropion as
adjuncts to mood stabilizers.  Am J Psychiatry 2006, 163:232-239.
16. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE Jr, McEl-
roy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA: Rate of
switch in bipolar patients prospectively treated with second-
generation antidepressants as augmentation to mood stabi-
lizers.  Bipolar Disord 2001, 3:259-265.
17. Himmelhoch J, Mulla D, Neil J, Detre T, Kupfer D: Incidence and
significance of mixed affective states in a bipolar population.
Arch Gen Psychiatry 1976, 33:1062-1066.
18. Bottlender R, Rudolf D, Strauss A, Moller HJ: Mood-stabilisers
reduce the risk of developing antidepressant-induced mani-
form states in acute treatment of bipolar I depressed
patients.  J Affect Disord 2001, 63:79-83.
19. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G: Treatment
of bipolar depression: an update.  J Affect Disord 2008, 109:21-34.
20. Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, Nimatoudis I,
Iacovides A, Kaprinis GS: A seven-year follow-up of an
extremely refractory bipolar I patient.  CNS Spectr 2007,
12:733-734.
21. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T,
Fresno D, Giannakopoulos P, Kaprinis GS: Treatment of bipolar
disorder: a complex treatment for a multi-faceted disorder.
Ann Gen Psychiatry 2007, 6:27.
22. Fountoulakis KN: The contemporary face of bipolar illness:
complex diagnostic and therapeutic challenges.  CNS Spectr
2008, 13:763-774.
23. Fountoulakis KN, Akiskal HS: Focus on bipolar illness.  CNS Spectr
2008, 13:762.
24. Vieta E, Goikolea JM: Atypical antipsychotics: newer options for
mania and maintenance therapy.  Bipolar Disord 2005, 7(Suppl
4):21-33.
25. Fountoulakis KN, Vieta E: Treatment of bipolar disorder: a sys-
tematic review of available data and clinical perspectives.  Int
J Neuropsychopharmacol 2008, 11:999-1029.
26. Zarate CA Jr, Tohen M: Double-blind comparison of the contin-
ued use of antipsychotic treatment versus its discontinuation
in remitted manic patients.  Am J Psychiatry 2004, 161:169-171.
27. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta
E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker RW,
Risser RC, Namjoshi MA, Evans AR, Breier A: A 12-week, double-
blind comparison of olanzapine vs haloperidol in the treat-
ment of acute mania.  Arch Gen Psychiatry 2003, 60:1218-1226.
28. Garcia-Amador M, Pacchiarotti I, Valenti M, Sanchez RF, Goikolea JM,
Vieta E: Role of aripiprazole in treating mood disorders.  Exp
Rev Neurother 2006, 6:1777-1783.
29. Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J: Clini-
cal and therapeutic implications of predominant polarity in
bipolar disorder.  J Affect Disord 2006, 93:13-17.
30. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y,
Morita S: 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]buty-
loxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new
putative antipsychotic drug with both presynaptic dopamine
autoreceptor agonistic activity and postsynaptic D2 recep-
tor antagonistic activity.  J Pharmacol Exp Ther 1995, 274:329-336.
31. Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwa-
hodo Y, Nishi T: Novel antipsychotic agents with dopamine
autoreceptor agonist properties: synthesis and pharmacol-
ogy of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-
2(1H)-quinolinone derivatives.  J Med Chem 1998, 41:658-667.
32. Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie
M, Kikuchi T: The novel antipsychotic aripiprazole is a partial
agonist at short and long isoforms of D2 receptors linked toAnnals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
Page 13 of 15
(page number not for citation purposes)
the regulation of adenylyl cyclase activity and prolactin
release.  Brain Res 2004, 1003:9-17.
33. Wood M, Reavill C: Aripiprazole acts as a selective dopamine
D2 receptor partial agonist.  Exp Opin Invest Drugs 2007,
16:771-775.
34. Lieberman JA: Dopamine partial agonists: a new class of antip-
sychotic.  CNS Drugs 2004, 18:251-267.
35. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD,
Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affin-
ity partial agonist at human dopamine D2 receptors.  J Phar-
macol Exp Ther 2002, 302:381-389.
36. Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel
antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazi-
nyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597)
on prolactin release from the rat anterior pituitary gland.  J
Pharmacol Exp Ther 1996, 277:137-143.
37. Yamada S, Harano M, Yokoo H, Tanaka M: Antagonistic effects of
OPC-14597, a novel antipsychotic drug, on quinpirole- and (-
)-sulpiride-induced changes in evoked dopamine release in
rat striatal slices.  J Pharm Pharmacol 1997, 49:206-208.
38. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization
of aripiprazole partial agonist activity at human dopamine
D3 receptors.  Eur J Pharmacol 2008, 597:27-33.
39. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF,
Ravert H, Suri A, Bramer S, Wong DF: Dopamine D2 and D3
receptor occupancy in normal humans treated with the
antipsychotic drug aripiprazole (OPC 14597): a study using
positron emission tomography and [11C]raclopride.  Neu-
ropsychopharmacology 2002, 27:248-259.
40. Bruins Slot LA, Palmier C, Tardif S, Cussac D: Action of novel
antipsychotics at human dopamine D3 receptors coupled to
G protein and ERK1/2 activation.  Neuropharmacology 2007,
53:232-241.
41. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S: Dif-
ferential effects of aripiprazole on D(2), 5-HT(2), and 5-
HT(1A) receptor occupancy in patients with schizophrenia:
a triple tracer PET study.  Am J Psychiatry 2007, 164:1411-1417.
42. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler
A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C,
Rösch F, Schaefer WM, Vernaleken I: Brain and plasma pharma-
cokinetics of aripiprazole in patients with schizophrenia: an
[18F]fallypride PET study.  Am J Psychiatry 2008, 165:988-995.
43. Novi F, Millan MJ, Corsini GU, Maggio R: Partial agonist actions of
aripiprazole and the candidate antipsychotics S33592, bife-
prunox, N-desmethylclozapine and preclamol at dopamine
D(2L) receptors are modified by co-transfection of D(3)
receptors: potential role of heterodimer formation.  J Neuro-
chem 2007, 102:1410-1424.
44. Etievant A, Betry C, Arnt J, Haddjeri N: Bifeprunox and aripipra-
zole suppress in vivo VTA dopaminergic neuronal activity via
D2 and not D3 dopamine autoreceptor activation.  Neurosci
Lett 2009, 460:82-86.
45. Chen SF, Shen YC, Chen CH: Effects of the DRD3 Ser9Gly poly-
morphism on aripiprazole efficacy in schizophrenic patients
as modified by clinical factors.  Prog Neuropsychopharmacol Biol
Psychiatry 2009, 33:470-474.
46. Bowles TM, Levin GM: Aripiprazole: a new atypical antipsy-
chotic drug.  Ann Pharmacother 2003, 37:687-694.
47. Grunder G, Carlsson A, Wong DF: Mechanism of new antipsy-
chotic medications: occupancy is not just antagonism.  Arch
Gen Psychiatry 2003, 60:974-977.
48. Ozdemir V, Fourie J, Ozdener F: Aripiprazole (Otsuka Pharma-
ceutical Co).  Curr Opin Invest Drugs 2002, 3:113-120.
49. Li Z, Ichikawa J, Dai J, Meltzer HY: Aripiprazole, a novel antipsy-
chotic drug, preferentially increases dopamine release in the
prefrontal cortex and hippocampus in rat brain.  Eur J Pharma-
col 2004, 493:75-83.
50. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The
antipsychotic aripiprazole is a potent, partial agonist at the
human 5-HT1A receptor.  Eur J Pharmacol 2002, 441:137-140.
51. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully
substitutes for the 5-HT1A receptor agonist LY293284 in the
drug discrimination assay in rats.  Psychopharmacology (Berlin)
2004, 172:415-421.
52. Goodnick PJ, Jerry JM: Aripiprazole: profile on efficacy and
safety.  Exp Opin Pharmacother 2002, 3:1773-1781.
53. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA,
Gonzalez AM, Sibley DR, Mailman RB: Interactions of the novel
antipsychotic aripiprazole (OPC-14597) with dopamine and
serotonin receptor subtypes.  Neuropsychopharmacology 1999,
20:612-627.
54. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan
T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction
of the novel antipsychotic aripiprazole with 5-HT1A and 5-
HT 2A receptors: functional receptor-binding and in vivo
electrophysiological studies.  Psychopharmacology (Berlin) 2007,
190:373-382.
55. Davies MA, Sheffler DJ, Roth BL: Aripiprazole: a novel atypical
antipsychotic drug with a uniquely robust pharmacology.
CNS Drug Rev 2004, 10:317-336.
56. Green B: Focus on aripiprazole.  Curr Med Res Opin 2004,
20:207-213.
57. Gupta S, Masand P: Aripiprazole: review of its pharmacology
and therapeutic use in psychiatric disorders.  Ann Clin Psychiatry
2004, 16:155-166.
58. Levine M, Traub S, Burns M: The pharmacology and toxicology
of aripiprazole.  Internet J Med Toxicol 2004, 7:5.
59. DeLeon A, Patel NC, Crismon ML: Aripiprazole: a comprehen-
sive review of its pharmacology, clinical efficacy, and tolera-
bility.  Clin Ther 2004, 26:649-666.
60. Caccia S: N-dealkylation of arylpiperazine derivatives: disposi-
tion and metabolism of the 1-aryl-piperazines formed.  Curr
Drug Metab 2007, 8:612-622.
61. Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL: Effects of hepatic
or renal impairment on the pharmacokinetics of aripipra-
zole.  Clin Pharmacokinet 2008, 47:533-542.
62. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill
M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripipra-
zole and its human metabolite are partial agonists at the
human dopamine D2 receptor, but the rodent metabolite
displays antagonist properties.  Eur J Pharmacol 2006, 546:88-94.
63. Boulton DW, Kollia G, Mallikaarjun S, Komoroski B, Sharma A, Koval-
ick LJ, Reeves RA: Pharmacokinetics and tolerability of intra-
muscular, oral and intravenous aripiprazole in healthy
subjects and in patients with schizophrenia.  Clin Pharmacokinet
2008, 47:475-485.
64. Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaar-
jun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A: Tolerability
and pharmacokinetics of aripiprazole in children and adoles-
cents with psychiatric disorders: an open-label, dose-escala-
tion study.  J Clin Psychopharmacol 2008, 28:441-446.
65. Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, Arias
AJ, Oncken C: Effects of aripiprazole on subjective and physi-
ological responses to alcohol.  Alcohol Clin Exp Res 2008,
32:573-579.
66. Voronin K, Randall P, Myrick H, Anton R: Aripiprazole effects on
alcohol consumption and subjective reports in a clinical lab-
oratory paradigm – possible influence of self-control.  Alcohol
Clin Exp Res 2008, 32:1954-1961.
67. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM,
Jones DN: Characterisation of olanzapine-induced weight
gain and effect of aripiprazole vs olanzapine on body weight
and prolactin secretion in female rats.  Psychopharmacology (Ber-
lin) 2005, 182:220-231.
68. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A,
Ingenito G: A placebo-controlled, double-blind study of the
efficacy and safety of aripiprazole in patients with acute bipo-
lar mania.  Am J Psychiatry 2003, 160:1651-1658.
69. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W,
Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T: Arip-
iprazole in the treatment of acute manic or mixed episodes
in patients with bipolar I disorder: a 3-week placebo-control-
led study.  J Psychopharmacol 2006, 20:536-546.
70. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN,
McQuade RD, Carson WH: Aripiprazole monotherapy in the
treatment of acute bipolar I mania: a randomized, double-
blind, placebo- and lithium-controlled study.  J Affect Disord
2009, 112:36-49.
71. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson
WH, Spiller NH, Torbeyns AF, Sanchez R: Aripiprazole mono-
therapy in acute mania: 12-week randomised placebo- and
haloperidol-controlled study.  Br J Psychiatry 2009, 194:40-48.Annals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
Page 14 of 15
(page number not for citation purposes)
72. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson
W, Abou-Gharbia N, Swanink R, Iwamoto T: Effectiveness of arip-
iprazole v. haloperidol in acute bipolar mania: double-blind,
randomised, comparative 12-week trial.  Br J Psychiatry 2005,
187:235-242.
73. Vieta E, T'Joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez
R, Owen R, Nameche L: Efficacy of adjunctive aripiprazole to
either valproate or lithium in bipolar mania patients partially
nonresponsive to valproate/lithium monotherapy: a pla-
cebo-controlled study.  Am J Psychiatry 2008, 165:1316-1325.
74. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P,
Oren DA: Management of acute agitation in patients with
bipolar disorder: efficacy and safety of intramuscular arip-
iprazole.  J Clin Psychopharmacol 2007, 27:171-176.
75. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Car-
son WH, Marcus RN, Owen R: Aripiprazole monotherapy in
nonpsychotic bipolar I depression: results of 2 randomized,
placebo-controlled studies.  J Clin Psychopharmacol 2008,
28:13-20.
76. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX,
Rollin LM, Marcus RN, Sanchez R: A randomized, double-blind,
placebo-controlled 26-week trial of aripiprazole in recently
manic patients with bipolar I disorder.  J Clin Psychiatry 2006,
67:626-637.
77. Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH,
Eudicone JM, Carlson BX, Marcus RN, Sanchez R: Aripiprazole
monotherapy for maintenance therapy in bipolar I disorder:
a 100-week, double-blind study versus placebo.  J Clin Psychiatry
2007, 68:1480-1491.
78. Muzina DJ, Momah C, Eudicone JM, Pikalov A, McQuade RD, Marcus
RN, Sanchez R, Carlson BX: Aripiprazole monotherapy in
patients with rapid-cycling bipolar I disorder: an analysis
from a long-term, double-blind, placebo-controlled study.  Int
J Clin Pract 2008, 62:679-687.
79. Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN: A prospec-
tive, open-label study of aripiprazole mono- and adjunctive
treatment in acute bipolar depression.  J Affect Disord 2008,
110:70-74.
80. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P: Effect of arip-
iprazole on self-reported anhedonia in bipolar depressed
patients.  Psychiatry Res 2009, 165:193-196.
81. McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B,
Leverich GS, Post RM, Keck PE Jr: Open-label aripiprazole in the
treatment of acute bipolar depression: a prospective pilot
trial.  J Affect Disord 2007, 101:275-281.
82. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P: Beneficial
acute antidepressant effects of aripiprazole as an adjunctive
treatment or monotherapy in bipolar patients unresponsive
to mood stabilizers: results from a 16-week open-label trial.
Exp Opin Pharmacother 2008, 9:3145-3149.
83. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM: Adjunc-
tive aripiprazole in treatment-resistant bipolar depression.
Ann Clin Psychiatry 2006, 18:169-172.
84. Schieber FC, Boulton DW, Balch AH, Croop R, Mallikaarjun S, Ben-
son J, Carlson BX: A non-randomized study to investigate the
effects of the atypical antipsychotic aripiprazole on the
steady-state pharmacokinetics of lamotrigine in patients
with bipolar I disorder.  Hum Psychopharmacol 2009, 24:145-152.
85. Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy
KA, Meyer WJ: Aripiprazole therapy in 20 older adults with
bipolar disorder: a 12-week, open-label trial.  J Clin Psychiatry
2008, 69:41-46.
86. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M: Arip-
iprazole augmentation in treatment-resistant bipolar
depression: early response and development of akathisia.
Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:574-577.
87. Kemp DE, Dago PL, Straus JL, Fleck J, Karaffa M, Gilmer WS: Arip-
iprazole augmentation for treatment-resistant bipolar
depression: sustained remission after 36 months.  J Clin Psy-
chopharmacol 2007, 27:304-305.
88. Sokolski KN: Adjunctive aripiprazole in bipolar I depression.
Ann Pharmacother 2007, 41:35-40.
89. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P,
Kotarski M, Aleardi M, Wozniak J: An open-label trial of aripipra-
zole monotherapy in children and adolescents with bipolar
disorder.  CNS Spectr 2007, 12:683-689.
90. Tramontina S, Zeni CP, Pheula GF, de Souza CK, Rohde LA: Arip-
iprazole in juvenile bipolar disorder comorbid with atten-
tion-deficit/hyperactivity disorder: an open clinical trial.  CNS
Spectr 2007, 12:758-762.
91. Barzman DH, DelBello MP, Kowatch RA, Gernert B, Fleck DE, Pathak
S, Rappaport K, Delgado SV, Campbell P, Strakowski SM: The effec-
tiveness and tolerability of aripiprazole for pediatric bipolar
disorders: a retrospective chart review.  J Child Adolesc Psychop-
harmacol 2004, 14:593-600.
92. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Fal-
z o n e  R ,  M i c k  E :  Aripiprazole in the treatment of pediatric
bipolar disorder: a systematic chart review.  CNS Spectr 2005,
10:141-148.
93. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L: Switching outpa-
tients with bipolar or schizoaffective disorders and sub-
stance abuse from their current antipsychotic to
aripiprazole.  J Clin Psychiatry 2005, 66:756-760.
94. Witschy JK, Winter AS: Improvement in tardive dyskinesia with
aripiprazole use.  Can J Psychiatry 2005, 50:188.
95. Lorenz RA, Weinstein B: Resolution of haloperidol-induced
hyperprolactinemia with aripiprazole.  J Clin Psychopharmacol
2007, 27:524-525.
96. Ali S, Pearlman RL, Upadhyay A, Patel P: Neuroleptic malignant
syndrome with aripiprazole and lithium: a case report.  J Clin
Psychopharmacol 2006, 26:434-436.
97. Desarkar P, Thakur A, Sinha VK: Aripiprazole-induced acute dys-
tonia.  Am J Psychiatry 2006, 163:1112-1113.
98. Henderson JB, Labbate L, Worley M: A case of acute dystonia
after single dose of aripiprazole in a man with cocaine
dependence.  Am J Addict 2007, 16:244.
99. Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, Iacovides A,
Kaprinis GS: Acute dystonia with low-dosage aripiprazole in
Tourette's disorder.  Ann Pharmacother 2006, 40:775-777.
100. Koener B, Hermans E, Maloteaux JM, Jean-Jean A, Constant EL: Par-
adoxical motor syndrome following a switch from atypical
neuroleptics to aripiprazole.  Am J Psychiatry 2007,
164:1437-1438.
101. Lindsey R, Kaplan D, Koliatsos V, Walters J, Sandson N: Aripipra-
zole and extrapyramidal symptoms.  J Am Acad Child Adoles Psy-
chiatry 2003, 42:1268-1269.
102. Schonberger RB, Douglas L, Baum CR: Severe extrapyramidal
symptoms in a 3-year-old boy after accidental ingestion of
the new antipsychotic drug aripiprazole.  Pediatrics 2004,
114:1743.
103. Behere RV, Venkatasubramanian G, Naveen MN, Gangadhar BN:
Aripiprazole-induced hyponatremia: a case report.  J Clin Psy-
chiatry 2007, 68:640-641.
104. Torgovnick J, Sethi NK, Arsura E: Aripiprazole-induced orthos-
tatic hypotension and cardiac arrhythmia.  Psychiatry Clin Neu-
rosci 2008, 62:485.
105. Gregoriou S, Karagiorga T, Stratigos A, Volonakis K, Kontochris-
topoulos G, Rigopoulos D: Photo-onycholysis caused by olanza-
pine and aripiprazole.  J Clin Psychopharmacol 2008, 28:219-220.
106. Aitchison K, Bienroth M, Cookson J, Gray R, Haddad P, Moore B,
Ratna L, Sullivan G, Taylor D, Taylor M, Goodwin GM: A UK con-
sensus on the administration of aripiprazole for the treat-
ment of mania.  J Psychopharmacol 2009, 23:231-240.
107. Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B: Efficacy
and safety of aripiprazole in subpopulations with acute
manic or mixed episodes of bipolar I disorder.  J Affect Disord
2008, 107:145-154.
108. Sachs GS, Gaulin BD, Gutierrez-Esteinou R, McQuade RD, Pikalov A
3rd, Pultz JA, Sanchez R, Marcus RN, Crandall DT: Antimanic
response to aripiprazole in bipolar I disorder patients is inde-
pendent of the agitation level at baseline.  J Clin Psychiatry 2007,
68:1377-1383.
109. Sanford M, Scott LJ: Intramuscular aripiprazole: a review of its
use in the management of agitation in schizophrenia and
bipolar I disorder.  CNS Drugs 2008, 22:335-352.
110. Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade
R, Pikalov AA 3rd, Crandall DT: Intramuscular aripiprazole in
the control of agitation.  J Psychiatr Pract 2007, 13:159-169.
111. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D: Pharma-
cological interventions for acute bipolar mania: a systematic
review of randomized placebo-controlled trials.  Bipolar Disord
2007, 9:551-560.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of General Psychiatry 2009, 8:16 http://www.annals-general-psychiatry.com/content/8/1/16
Page 15 of 15
(page number not for citation purposes)
112. Cipriani A, Rendell JM, Geddes JR: Haloperidol alone or in com-
bination for acute mania.  Cochrane Database Syst Rev 2006,
3:CD004362.
113. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr: Atypical
antipsychotics in the treatment of mania: a meta-analysis of
randomized, placebo-controlled trials.  J Clin Psychiatry 2006,
67:509-516.
114. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konar-
ski JZ: Aripiprazole: pharmacology and evidence in bipolar
disorder.  Exp Opin Pharmacother 2007, 8:1001-1009.
115. McIntyre RS, Woldeyohannes HO, Yasgur BS, Soczynska JK, Miranda
A, Konarski JZ: Maintenance treatment in bipolar disorder: a
focus on aripiprazole.  Exp Rev Neurother 2007, 7:919-925.